Market closed

PTC Therapeutics/$PTCT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Ticker

$PTCT
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
South Plainfield, United States

Employees

1,022
Website
www.ptcbio.com

PTC Therapeutics Metrics

BasicAdvanced
$3.7B
Market cap
-
P/E ratio
-$5.93
EPS
0.63
Beta
-
Dividend rate
$3.7B
0.63
$49.44
$23.58
846K
2.098
2.003
-209.407
-235.43
-0.75%
-5.15%
52.54%
4.018
-3.46
-2.48
-13.199
12.84%
-31.52%
22.31%
-3.01%

What the Analysts think about PTC Therapeutics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.

PTC Therapeutics Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PTC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

PTC Therapeutics News

AllArticlesVideos
PTC Therapeutics Stock Soars on Novartis Licensing Agreement

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Investopedia·2 weeks ago
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

Benzinga·2 weeks ago
PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

Reuters·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PTCT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for PTC Therapeutics stock?

PTC Therapeutics (PTCT) has a market cap of $3.7B as of December 14, 2024.

What is the P/E ratio for PTC Therapeutics stock?

The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 0 as of December 14, 2024.

Does PTC Therapeutics stock pay dividends?

No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of December 14, 2024.

When is the next PTC Therapeutics dividend payment date?

PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.

What is the beta indicator for PTC Therapeutics?

PTC Therapeutics (PTCT) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.